J&J additionally wished to construct a casual alliance with its opponents that it hoped would enable the trade to talk with one voice concerning the security of the vaccines and handle any public concerns concerning the blood-clot instances, the Journal reported.
In a press release to NCS on Friday, a Pfizer (PFE)
spokesperson declined to touch upon the specifics of the WSJ report. “Pfizer embraces opportunities for scientific exchange when we can make a meaningful contribution that is not being represented by other groups or regulators,” the spokesperson mentioned. “We have and will continue to collaborate with other vaccine makers as appropriate as we all fight against this deadly pandemic.”
declined to remark. AstraZeneca (AZN)
did not instantly reply to a request for remark.
Johnson & Johnson (JNJ)
instructed NCS in an e-mail that “the safety of the patients who use our products is our top priority,” and that the corporate is actively working the US and European authorities. The firm additionally famous that the pandemic has resulted in “unprecedented collaboration and sharing of publicly available data and information,” additional including “we believe collaborative scientific exchange can lead to more robust answers to questions.”
The information comes simply three days after the Centers for Disease Control and Prevention and the Food and Drug Administration really helpful pausing using the Johnson & Johnson vaccine, following six reported US instances of a uncommon and extreme sort of blood clot.
All six instances had been amongst ladies between the ages of 18 and 48, the businesses mentioned in a press release, and signs occurred six to 13 days after vaccination. The advice to pause comes out of “an abundance of caution,” they added, and these instances “appear to be extremely rare.”
— NCS’s Nadia Kounang contributed to this report.